Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,847 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Tumor Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

WTC Chest CT Imaging Archive

NCT03295279
View directory record Official record
Conditions
Chronic Airway Disease, Interstitial Lung Disease, Lung Cancer
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2,122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

NCT02934503
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Etoposide, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Platinum-based chemotherapy, REGN7075
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
15
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Completed No phase listed Observational

TS Overexpression in SCLC: Mechanism and Therapeutic Targeting

NCT03741829
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

NCT00998166
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed, Cisplatin, Bevacizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Lake Success, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00528645
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion, Recurrent Small Cell Lung Cancer
Interventions
saracatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

NCT03088813
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Irinotecan liposome injection, Topotecan
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Incorporating Veterans' Preferences Into Lung Cancer Screening Decisions

NCT02899754
View directory record Official record
Conditions
Lung Cancer Screening
Interventions
Lung Cancer Screening Decision Tool, Control Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
West Haven, Connecticut • Philadelphia, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

NCT00858403
View directory record Official record
Conditions
Lung Cancer
Interventions
Dasatinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

NCT03064854
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT02468661
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
INC280 single agent, erlotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Active, not recruiting No phase listed Observational

Early Detection of Lung Cancer

NCT03181256
View directory record Official record
Conditions
Lung Cancer
Interventions
Biospecimen collection, Pulmonary Function Test, Computed Tomography (CT), Laboratory Biomarker
Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
55 Years to 80 Years
Enrollment
45 participants
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

NCT04372927
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Pemetrexed
Drug · Biological · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Jul 22, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest

NCT05354570
View directory record Official record
Conditions
Thymic Malignancies, Pleural Metastases
Interventions
Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01253369
View directory record Official record
Conditions
Small Cell Lung Cancer, Lung Cancer, SCLC
Interventions
Pazopanib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932451
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
140
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

NCT01770418
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Radiation with Concurrent Chemotherapy
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

NCT04079179
View directory record Official record
Conditions
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
Interventions
Cobimetinib
Drug
Lead sponsor
Carl Allen
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Computer-Assisted Counseling in Helping African American Smokers Stop Smoking

NCT00310141
View directory record Official record
Conditions
Lung Cancer
Interventions
Smoking cessation intervention, Counseling intervention, Nicotine patch
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Jul 22, 2026, 5:05 PM EDT